• Deep Yellow announces major construction contracts for Tumas Project

    A woman working in construction leans against a piece of machinery wearing a hi vis vest and a hardhat, smiling.

    The Deep Yellow Ltd (ASX: DYL) share price is in focus today after the company secured two major civil and concrete construction contracts for its Tumas Project in Namibia, valued at approximately A$34 million, further de-risking its flagship uranium development.

    What did Deep Yellow report?

    • Two major civil and concrete construction contracts awarded for the Tumas Project in Namibia.
    • Estimated combined contract value of around A$34 million, following a competitive tender process.
    • Contracts awarded to 100% Namibian-owned contractors, supporting local content.
    • Work packages cover processing plant concrete, precast infrastructure, and Run-of-Mine retaining structures.
    • Mobilisation scheduled for August 2026 with sequential handover to reduce execution risk.

    What else do investors need to know?

    Both contracts were awarded to Namibian Construction Pty Ltd and Nexus Building and Civils Contractors Pty Ltd, reinforcing Deep Yellow’s focus on in-country capability and local workforce participation. The company said the process followed industry-standard terms and competitive tendering.

    Civil and concrete works will be delivered sequentially from August 2026. While they do not alter the planned 24-month construction schedule after the Final Investment Decision, the work is expected to create multiple work fronts and greater project flexibility.

    What did Deep Yellow management say?

    Managing Director and CEO Greg Field said:

    These awards represent another important milestone in our disciplined approach to project development. Our objective has always been to systematically remove execution risk, secure high-quality contractors and ensure the Project is positioned for efficient delivery as we advance toward FID towards the end of this year. Civil and concrete works are fundamental to the successful delivery of any major processing facility. Securing these capabilities now creates multiple construction work fronts, increasing execution flexibility and strengthening confidence in execution once FID is reached.

    We are equally pleased that both contracts have been awarded to highly capable Namibian companies. Developing Tumas in partnership with local industry is central to our strategy and reflects our commitment to delivering long-term value for Namibia alongside our shareholders.

    What’s next for Deep Yellow?

    Deep Yellow is progressing towards a Final Investment Decision for the Tumas Project, expected in the fourth quarter of 2026. The company continues to pursue its dual-pillar growth strategy, aiming to become a globally significant uranium producer.

    Its development pipeline also includes the Mulga Rock Project in Western Australia, and exploration projects in the Northern Territory and Namibia. With a strong focus on partnership and project execution, Deep Yellow expects to deliver long-term value for communities, shareholders and the uranium supply chain.

    Deep Yellow share price snapshot

    Over the past 12 months, Deep Yellow shares have declined 33%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 1% over the same period.

    View Original Announcement

    The post Deep Yellow announces major construction contracts for Tumas Project appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Deep Yellow right now?

    Before you buy Deep Yellow shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Deep Yellow wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 16 June 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

  • Fletcher Building secures $60m for local cement production in NZ

    A smiling businessman sits at a desk with bags of money, indicating a share price rise after funding has been approved

    The Fletcher Building Ltd (ASX: FBU) share price is in focus today after the company announced a government-backed funding agreement to secure New Zealand’s only domestic cement manufacturing until at least 2040. Golden Bay Cement, part of Fletcher Building, will receive up to $60 million from the New Zealand Government to continue operations and invest in decarbonisation.

    What did Fletcher Building report?

    • Golden Bay Cement to get up to $60 million in government support for its Northland plant
    • Commitment to continue cement production until at least 2040
    • Planned investment of at least $150 million at the Northland facility through to 2040
    • Supports domestic supply of around 60% of New Zealand’s cement
    • Agreement aims to address the carbon cost gap versus imported cement

    What else do investors need to know?

    The arrangement is a one-off government response to ensure domestic cement supply and national infrastructure resilience. Without this support, rising costs—especially from carbon emissions—could have forced Golden Bay Cement to close and shift to imports by 2030.

    The agreement also ensures Golden Bay Cement will keep investing in upgrades and alternative fuels, which have already reduced reliance on fossil fuels. The plant directly employs more than 150 people and underpins over 600 jobs across the Whangārei district.

    What did Fletcher Building management say?

    Andrew Reding, Fletcher Building Chief Executive Officer and Managing Director, said:

    Domestic cement production matters for New Zealand’s resilience as much as for its economics. An onshore source reduces exposure to shipping disruption, supply shocks and price volatility, an increasingly important consideration as global supply chains become more unpredictable. Golden Bay Cement directly employs more than 150 people and supports a further 450 jobs across the Whangārei district, underpinning our ability to build homes, hospitals, roads and infrastructure with locally sourced materials.

    What’s next for Fletcher Building?

    With this funding agreement, Fletcher Building will phase in at least $150 million of investment at Golden Bay Cement’s Northland plant up to 2040. The focus will be on operational resilience, modernisation, and decarbonisation, with all planned investments subject to Fletcher Building’s usual approval processes.

    The company’s commitment secures local cement manufacturing, aiming for a lower-carbon operation compared to imports and supporting New Zealand’s building sector.

    Fletcher Building share price snapshot

    Over the past 12 months, Fletcher Building shares have risen 13%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 1% over the same period.

    View Original Announcement

    The post Fletcher Building secures $60m for local cement production in NZ appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Fletcher Building right now?

    Before you buy Fletcher Building shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Fletcher Building wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 16 June 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

  • Could CSL shares double from here? Here’s what the experts think

    One girl leapfrogs over her friend's back.

    CSL Ltd (ASX: CSL) shares finished last week 1% higher at $123.32, extending their recent rebound. The biotech giant’s shares have climbed 16% over the past month and are now up around 34% since their early June lows.

    Even so, it’s important to keep that rally in perspective. CSL shares remain down about 29% in 2026 and have lost roughly half their value over the past 12 months.

    So, after one of the biggest falls in the company’s history, could CSL shares double from here and reclaim their former highs?

    Changed narrative

    For decades, CSL built a reputation as one of the ASX’s highest-quality companies, delivering consistent earnings growth through its leadership in plasma-derived therapies and global healthcare operations.

    That reputation took a major hit over the past year.

    A string of earnings downgrades, leadership changes, and around US$5 billion in non-cash impairments, largely tied to the CSL Vifor acquisition, have weighed heavily on investor confidence.

    Impairments, downward guidance

    For almost two years, the ASX biotech stock has been locked in a persistent downtrend. This has been punctuated by sharp 10% to 15% rallies before another disappointing update pushed shares to fresh multi-year lows.

    The latest setback came in May, when management guided to FY26 revenue of around US$15.2 billion, about 4% below consensus forecasts, and NPAT of roughly US$3.1 billion, around 7% below expectations. The company also flagged another US$5 billion of non-cash impairments across FY26 and FY27.

    Since then, little has changed fundamentally. While Tavneos faces potential withdrawal in the US and Europe, analysts note the product contributes only around 1% of group revenue.

    The team at Macquarie Group Ltd (ASX: MQG) believes expectations have now been reset to a relatively low level. Analysts expect modest earnings growth through FY28 and argue that even small earnings beats could support the share price.

    What do the experts think?

    Broker sentiment has become more cautious than it was a year ago.

    According to TradingView data, 10 of 18 analysts now rate CSL shares as a hold. The remaining eight have buy or strong buy recommendations. The average price target sits at $138.88, implying around 13% upside from current levels.

    Some analysts remain far more optimistic. UBS retained its buy rating at the start of this month with a $158 price target. The broker argues that much of the bad news surrounding Vifor has already been priced into the shares.

    Morgans is also positive, maintaining a buy recommendation and a $147.59 target price. However, it expects a recovery in investor confidence to take time as the market waits for clearer evidence that earnings have stabilised.

    A handful of analysts reportedly see the shares reaching as high as $197.85 over the next year. That represents potential gains of about 60%.

    That would be an impressive recovery, but still well short of doubling from current levels. Based on current broker forecasts, a return to CSL’s record highs appears more realistic over several years than within the next 12 months.

    The post Could CSL shares double from here? Here’s what the experts think appeared first on The Motley Fool Australia.

    Should you invest $1,000 in CSL right now?

    Before you buy CSL shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 16 June 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has recommended CSL and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Sorry, but nothing was found. Please try a search with different keywords.